Trial Information

Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy

OBJECTIVES:

- Determine the effects of in vivo rituximab purging and maintenance on progression-free
survival in patients with relapsed or resistant follicular non-Hodgkin's lymphoma
undergoing high-dose chemotherapy.

- Determine the effects of this regimen on response rate and overall survival in this
patient population.

- Determine the effects of in vivo purging with rituximab on molecular remission rates in
the hematopoietic product and the patients.

- Determine the safety of rituximab in the transplant setting.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
according to type of remission (complete vs good partial) and which remission (second vs
third). Patients are randomized to one of four treatment arms.

All patients receive induction chemotherapy comprising cyclophosphamide IV over 3-4 hours on
day 0 or a standard induction chemotherapy regimen. Filgrastim (G-CSF) is administered
subcutaneously daily beginning on day 1.

Patients are then randomized to receive either in vivo rituximab purging or no purging
following restaging after completion of induction. For those patients receiving purging
(arms I and II), rituximab is administered IV once weekly for 4 weeks.

Peripheral blood stem cells (PBSC) are collected between days 8 and 12 post induction
chemotherapy. Within 4 weeks of PBSC collection, patients receive carmustine IV over 2 hours
on day -6, etoposide IV over 2 hours on days -5 to -2, cytarabine IV over 5 minutes twice
daily on days -5 to -2, and melphalan IV over 10-15 minutes on day -1. (Alternatively, high
dose cyclophosphamide and total body irradiation beginning 2-4 weeks after cyclophosphamide
or standard induction chemotherapy priming is also allowed.) PBSC are reinfused on day 0.

Patients are further randomized to receive either rituximab maintenance or observation only.
For those patients receiving maintenance (arms I and III), rituximab is administered IV once
every 2 months for 4 doses beginning 30 days after PBSC reinfusion.

Patients are followed at 30 days, 3, 6, 9, and 12 months after PBSC transplant, every 6
months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 460 patients (115 per treatment arm) will be accrued for this
study within 5 years.